Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates
10:35pm, Wednesday, 08'th Mar 2023 Zacks Investment Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
11:00pm, Tuesday, 07'th Mar 2023 GlobeNewswire Inc.
ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based thera
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
06:00pm, Tuesday, 07'th Mar 2023
ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therape
MacroGenics to Participate in Upcoming Investor Conferences
09:30pm, Thursday, 02'nd Mar 2023 GlobeNewswire Inc.
ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for
MacroGenics to Participate in Upcoming Investor Conferences
04:30pm, Thursday, 02'nd Mar 2023
ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the
NanoString Technologies (NSTG) Reports Q4 Loss, Tops Revenue Estimates
10:15pm, Tuesday, 28'th Feb 2023 Zacks Investment Research
NanoString (NSTG) delivered earnings and revenue surprises of -55.74% and 3.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in MacroGenics (MGNX): Can Its 25.7% Jump Turn into More Strength?
02:56pm, Monday, 20'th Feb 2023 Zacks Investment Research
MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the
AutoNation, HubSpot, AMC Networks And Other Big Stocks Moving Higher On Friday
03:07pm, Friday, 17'th Feb 2023 Benzinga
U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Friday. Here are some big stocks recording gains in today’s session.
AMC Networks Inc. (NASDAQ: AMCX) shares surged
Around $11M Bet On Insight Enterprises? Check Out These 4 Stocks Insiders Are Buying
12:58pm, Friday, 17'th Feb 2023 Benzinga
Although US stocks closed lower on Thursday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stoc
ROCKVILLE, MD, Feb. 13, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based thera
MacroGenics to Participate in Upcoming Investor Conferences
09:30pm, Monday, 06'th Feb 2023 GlobeNewswire Inc.
ROCKVILLE, MD, Feb. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for t
MacroGenics to Participate in Upcoming Investor Conferences
04:30pm, Monday, 06'th Feb 2023
ROCKVILLE, MD, Feb. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the
SurModics (SRDX) Surges 6.1%: Is This an Indication of Further Gains?
12:57pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i
The Latest Analyst Ratings for Macrogenics
01:00pm, Thursday, 19'th Jan 2023 Benzinga
Macrogenics (NASDAQ:MGNX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
1
0
0
Last 30D
Tesla To Rally Around 138%? Here Are 10 Other Analyst Forecasts For Thursday
12:57pm, Thursday, 19'th Jan 2023 Benzinga
JP Morgan cut the price target for Apple Inc. (NASDAQ: AAPL) from $190 to $180. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares fell 1.1% to $133.70 in pre-market tr
